Non-Disease-Specific Pharmacology/Therapeutics
15 cases on live-vaccine timing after B-cell-depleting biologics, rapid drug desensitization protocol selection, perioperative JAK-inhibitor hold intervals, venom immunotherapy with concurrent beta-blockade, updosed antihistamine therapy limits, cumulative glucocorticoid burst exposure, biosimilar substitution, epinephrine autoinjector access and cost, epinephrine use on MAOIs, renal dose-adjustment thresholds, untested dual-biologic combinations, allergen selection under limited immunotherapy tolerance, pharmacogenomic screening before allopurinol, anti-drug antibody-driven secondary loss of response, and extended first-dose observation windows — choose a case below to open its full multi-voice debate.
A woman on maintenance rituximab for EGPA needs a mandatory yellow fever vaccine before an overseas assignment — testing how firm the 6-month live-vaccine washout really is.
A pregnant woman needing penicillin for neurosyphilis and a chemotherapy patient with IgE-mediated oxaliplatin hypersensitivity both need the same tool — rapid desensitization — chosen very differently.
A man with severe atopic dermatitis on upadacitinib faces a scheduled knee replacement — testing whether a perioperative hold rule written for rheumatoid arthritis actually transfers to dermatology.
A beekeeper with post-MI metoprolol and life-threatening bee venom anaphylaxis tests whether a decades-old relative contraindication between beta-blockers and immunotherapy still holds up.
A commercial driver with chronic urticaria on maximized second-generation antihistamine therapy still can't sleep through the itch — testing whether a first-generation add-on at night is worth the sedation risk his job can't absorb.
A man with recurring asthma/sinus flares treated with prednisone bursts for years finally shows real bone loss — testing exactly when accumulated steroid exposure crosses from monitored to mandate-a-biologic.
A woman stable on branded Xolair for years is offered pharmacy-level substitution to an interchangeable biosimilar the week it reaches market — testing what continuity of response actually means for a drug, not a person.
A college student who can't afford a branded epinephrine autoinjector is offered a cheaper compounded prefilled syringe — testing what's actually gained and lost against two real FDA-approved alternatives.
A woman on phenelzine for treatment-resistant depression develops a new, confirmed shellfish anaphylaxis — testing whether a decades-old MAOI-epinephrine caution should ever override the treatment for a life-threatening reaction.
A man with severe atopic dermatitis on upadacitinib develops progressive diabetic nephropathy — testing exactly where his declining eGFR crosses the labeled dose-reduction threshold, and what happens after it does.
A woman with both severe eosinophilic asthma and treatment-refractory chronic urticaria needs two biologics whose mechanisms overlap — testing a combination no randomized trial has actually studied.
A polysensitized man with a punishing travel schedule can tolerate only a fraction of the injection burden his full allergen panel would require — testing how immunotherapy should actually be prioritized when everything can't be treated.
A man of Han Chinese descent with recurrent gout is about to start allopurinol without HLA-B*58:01 screening — testing whether a rare but catastrophic drug reaction justifies a delay his primary care doctor sees as unnecessary.
A woman whose dramatic response to dupilumab suddenly reverses after fourteen months tests whether a titer test, not a guess, should decide between dose-intensifying and switching agents entirely.
A man with indolent systemic mastocytosis about to receive his first omalizumab dose tests how far a standard observation window should stretch when the labeled default wasn't written with his risk factors in mind.